Everolimus/Lanreotide Prolongs PFS in Unresectable/Recurrent GEP-NETs
Everolimus plus lanreotide elicited a PFS of 29.7 months compared with 11.5 months from everolimus monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.
Related Articles
Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grants, in Partnership with Pelotonia & AACR
$700,000 over three years for female associate professors performing research that has a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis,…
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Undergraduate Summer Scholarship Scheme – The Institute of Cancer Research, London
Our paid undergraduate summer scholarships offer undergraduate students a chance to gain hands-on cancer research experience.
Program Guide – ASCO Meeting Program Guide
Moazzam Shahzad H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Moazzam Shahzad , Ahmad Basharat , Sohaib Irfan , Jawad Noor…
After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency – The Cancer Letter
In 1999, Richard Pazdur, a GI oncologist at MD Anderson, saw an FDA recruitment ad in The New England Journal of Medicine. The agency was…
Program Guide – ASCO Meeting Program Guide
Dae Kim H. Lee Moffitt Cancer Center and Research Institute Dae Kim , Lauren Ponto , Allan Pereira , Richard Kim , Chandler Kracht ,…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Home | AML Hub
Online resource for healthcare professionals, providing information, news & support relating to AML
NCCN publishes patient resource on genetic testing to guide patient decisionmaking – The Cancer Letter
The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The…
Translational Science Training Course
The ASTCT Translational Science Training Course is a program for young researchers and scientists involved in bench and translational science in the hematopoietic stem cell…
